ProNAi Therapeutics (NASDAQ:DNAI) has received a short term rating of buy from experts at Zacks with a rank of 2. The stock has been rated an average of 2.5 by 4 Brokerage Firm. 1 Wall Street Firms have rated the stock as a strong buys. 3 Brokerage Firms have advised hold.
Other Equity analysts have also commented on the company shares. Jefferies downgrades their rating on the shares of ProNAi Therapeutics (NASDAQ:DNAI). The current rating of the shares is Hold. Earlier, the shares were rated a Buy by the brokerage firm. The rating by the firm was issued on June 6, 2016.
ProNAi Therapeutics (NASDAQ:DNAI): The mean estimate for the short term price target for ProNAi Therapeutics (NASDAQ:DNAI) stands at $11.63 according to 4 Analysts. The higher price target estimate for the stock has been calculated at $35 while the lower price target estimate is at $3.
ProNAi Therapeutics (NASDAQ:DNAI) witnessed a decline in the market cap on Tuesday as its shares dropped 1.94% or 0.04 points. After the session commenced at $2.08, the stock reached the higher end at $2.08 while it hit a low of $1.98. With the volume soaring to 902,613 shares, the last trade was called at $2.02. The company has a 52-week high of $33.75. The company has a market cap of $61 million and there are 30,174,778 shares in outstanding. The 52-week low of the share price is $1.86.
Shares of ProNAi Therapeutics, Inc. appreciated by 6.32% during the last five trading days but lost 65.29% on a 4-week basis. ProNAi Therapeutics, Inc. has dropped 71.39% during the last 3-month period . Year-to-Date the stock performance stands at -86.57%.
ProNAi Therapeutics, Inc. is a clinical-stage oncology company. The Company develops and commercializes a portfolio of therapeutics based on its deoxyribonucleic acid interference (DNAi) technology platform for patients with cancer and hematological diseases. The Companys lead DNAi product candidate, PNT2258, treat cancers that overexpress BCL2, an oncogene known to be dysregulated in many types of cancer. Its platform consists of two components: Rationally-Designed DNAi Oligonucleotides and Lipid Nanoparticle (LNP) Delivery Technology. The Company has conducted two clinical trials for PNT2258: a Phase I safety trial in patients with relapsed or refractory solid tumors and a Phase II trial in patients with relapsed or refractory non-Hodgkins lymphoma (NHL). It has initiated Wolverine, a Phase II trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.